Nanox Issues Preliminary Q2 2026 Results as Cash Crunch Raises Going-Concern Doubts
I'm LongbridgeAI, I can summarize articles.Nano-X Imaging reported preliminary Q2 2026 results, citing revenue growth from teleradiology and AI solutions but warning of severe liquidity issues. With cash reserves around $31.4 million, the company stated there is substantial doubt about its ability to continue as a going concern for the next 12 months. Despite operational progress, including new U.S. deals and UK partnerships, analyst sentiment remains neutral due to persistent losses and cash burn.
An announcement from Nano-X Imaging ( (NNOX) ) is now available.
On July 23, 2026, Nanox reported preliminary unaudited results for the quarter ended June 30, 2026, alongside a business update that underscores both commercial traction and financial strain. The company highlighted growing revenue streams from teleradiology, imaging systems and AI solutions, but also disclosed a sharp decline in liquidity and warned that existing cash and deposits likely will not fund operations for 12 months, raising substantial doubt about its ability to continue as a going concern.
Operationally, Nanox signed another U.S. capital equipment deal for its Nanox.ARC system, prepared multiple new ARC and ARC X installations, and completed the first Nanox Imaging Network installation in Philadelphia ahead of initial patient scans and commercial activation. The company also struck a three-year reseller agreement with Vertec Scientific to distribute its Nanox.AI Bone solution in the U.K., reinforcing its AI footprint, while acknowledging that its preliminary figures, including revenue of roughly $4.0–$4.1 million and cash of about $31.4 million, remain subject to change pending completion of its close process and potential impairment assessments.
The most recent analyst rating on (NNOX) stock is a Hold
with a $3.00 price target.
To see the full list of analyst forecasts on Nano-X Imaging stock,
see the NNOX Stock Forecast page.
Spark’s Take on NNOX Stock
According to Spark, TipRanks’ AI Analyst, NNOX is a Neutral.
The score is primarily held down by weak financial performance (large ongoing losses and persistent cash burn) and the earnings-call risks (withdrawn revenue guidance and going-concern warning despite operational progress). Valuation is difficult to support with a negative P/E and no dividend. Technical analysis impact is limited due to missing indicator data, with only elevated volatility (beta 1.57) observable.
To see Spark’s full report on NNOX stock,
click here.
More about Nano-X Imaging
Nanox Imaging Ltd. is an Israel-based medical imaging technology company listed on Nasdaq that focuses on enabling preventive healthcare through an integrated imaging and healthcare services platform. Its ecosystem spans affordable digital X-ray hardware, AI algorithms for CT interpretation, cloud-based software, teleradiology via USARAD, and health IT solutions under Nanox Health IT, aiming to expand access to imaging beyond traditional hospitals and improve early disease detection.
The company’s core products include the Nanox.ARC 3D digital tomosynthesis system, Nanox.AI analytical tools, Nanox.CLOUD for secure image management, and complementary marketplace and IT services designed to streamline workflows and support more efficient care delivery worldwide.
Average Trading Volume: 2,201,690
Technical Sentiment Signal: Sell
Current Market Cap: $75.17M